Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medica

New Zealand research has demonstrated that a cardiovascular polypill can improve adherence to medicines proven to improve survival. Medicines are only effective if we take them although in New Zealand only a fraction of people that have suffered a cardiovascular event (heart attack or stroke) take the medicines proven to make them live longer. This study compared maori and non-maori patients in an effort to determine if a polypill can reduce gaps between the two groups.

Prior to study enrollment, the use of all recommended cardiovascular preventative medications (antiplatelet, statin and two antihypertensives) was 36% among Māori and 51% among non-Māori participants.

At 12 months, polypill-based care was associated with a significant increase in the use of recommended medications among both Māori and non-Māori compared with usual care.

Analysis showed that the polypill improvement was similar across both maori and non-maori.

New Zealand has a unique population mix and significant disparities in healthcare occur between ethnicities.

The cardiovascular polypill offers a means in which to address these disparities and improve the cardiovascular health of New Zealanders.

For more information please visit the Māori Health Review or Sage Journals.


Recent Posts

See All

PO Box 46205,
Herne Bay 1147,
Auckland, New Zealand

0800 832 724



Contact Us

Copyright © 2013 TeArai BioFarma Limited.